AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
The above is the analysis of the conflicting points in this earnings call
2.2% for the second quarter of 2025. - This growth was driven by strong performance in digital sales, which increased by 23% year-over-year, and pharmacy, with pharmacy sales growing 19% year-over-year. - The growth was attributed to enhanced customer value propositions through targeted promotions and personalized digital experiences, leveraging their extensive digital platforms and media collective.50 basis point improvement in the selling and administrative expense rate compared to the previous year.The savings are being reinvested into strategic growth initiatives and offsetting inflationary headwinds.
Pharmacy and Cross-selling Strategy:
19% year-over-year, driven by ongoing growth in GLP-1 products and increased core prescription volume.The company is focusing on converting single-channel shoppers into high-value cross-shoppers by integrating pharmacy and health solutions.
E-commerce and Customer Experience:
23% year-over-year, contributing to the overall 2.2% adjusted identical sales growth.Discover what executives don't want to reveal in conference calls

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet